We study the molecular mechanisms that govern neuronal communication, with a particular focus on how presynaptic proteins control neurotransmitter release, synaptic vesicle organization, and recycling. We are especially interested in how disruption of these processes contributes to the onset and progression of neurodegenerative diseases.

To address these questions, we integrate CRISPR/Cas9-based genome engineering approaches—including acute gene knockout, knock-in, and locus-specific activation or repression—across cell lines, mouse primary neurons, and human iPSC-derived neurons. These models are combined with live-cell and super-resolution imaging, ultrastructural analysis by electron microscopy, electrophysiological, and biochemical and proteomic approaches, allowing us to directly link molecular mechanisms to synaptic function.

A central goal of the lab is to develop and optimize gene therapy strategies. By leveraging in vivo gene delivery and genome editing technologies, we aim to advance next-generation, disease-modifying therapeutics for neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease.